Neurological Disorders Stocks
Biotechnology and healthcare service providers in this sector develop therapeutic interventions and rehabilitative frameworks for pathologies affecting the central and peripheral nervous systems.
As of Oct 23, 2026, Neurological Disorders has 85 US-listed companies worth $845B combined. The median member moved +1.5% over the past week; BHVN led among the 25 largest at +28.8% and RGC trailed at -20.0%.
Companies in Neurological Disorders
- ABBV – AbbVie Inc, $505B
- SNY – Sanofi ADR, $99.7B
- BSX – Boston Scientific Corp, $66.7B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- BIIB – Biogen Inc, $37B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- ALKS – Alkermes Plc, $7.4B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- PTCT – PTC Therapeutics Inc, $5.3B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- DFTX – Definium Therapeutics, Inc., $4.4B
- ITGR – Integer Holdings Corp, $4.3B
- LIVN – LivaNova PLC, $4.3B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- DNLI – Denali Therapeutics Inc, $3B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- BHC – Bausch Health Companies Inc, $2.4B
- HRMY – Harmony Biosciences Holdings, $2.1B
- BHVN – Biohaven Ltd., $1.8B
- STOK – Stoke Therapeutics Inc, $1.7B
- QURE – Uniqure NV, $1.6B
- GHRS – GH Research PLC, $1.3B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- ANRO – Alto Neuroscience, Inc., $956M
- CBLL – CeriBell, Inc, $888M
- ANNX – Annexon Inc, $726M
- ZVRA – Zevra Therapeutics Inc., $676M
- DRUG – Bright Minds Biosciences Inc, $506M
- BWAY – Brainsway Ltd, $474M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- OVID – Ovid Therapeutics Inc, $441M
- PRTA – Prothena Corporation plc, $435M
- NPCE – Neuropace Inc, $435M
- NGNE – Neurogene Inc, $431M
- ACIU – AC Immune Ltd, $256M
- ACOG – Alpha Cognition Inc, $192M
- PEPG – PepGen Ltd, $166M
- NGEN – NervGen Pharma Corp., $166M
- QTRX – Quanterix Corp, $163M
- TLSA – Tiziana Life Sciences Ltd, $144M
- AVXL – Anavex Life Sciences Corp, $121M
- COYA – Coya Therapeutics, Inc. Common Stock, $116M
- SPRB – Spruce Biosciences, Inc. Common Stock, $116M
- NERV – Minerva Neurosciences Inc, $112M
- PLYX – Polaryx Therapeutics, Inc. Common Stock, $98.2M
- IMUX – Immunic Inc, $95.4M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- ECOR – Electrocore LLC, $87.6M
- PMN – ProMIS Neurosciences Inc., $74.3M
- MNOV – MediciNova Inc, $73.8M
- ATHE – Alterity Therapeutics Ltd, $66.8M
- MYO – Myomo Inc, $49.1M
- LONA – LeonaBio, Inc., $49M
- CLNN – Clene Inc., $47M
- SER – Serina Therapeutics Inc, $45.5M
- ANVS – Annovis Bio Inc, $42.3M
- CRVO – CervoMed Inc., $35.4M
- IRLA – IRulya Therapeutics Inc., $35M
- IBO – Impact BioMedical, Inc., $34M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- PBM – Psyence Biomedical Ltd. Common Shares, $19.1M
- NEUP – Neuphoria Therapeutics Inc, $18.8M
- LFWD – ReWalk Robotics Ltd, $17.6M
- NCEL – NewcelX Ltd., $16.5M
- BIVI – Biovie Inc, $11.9M
- AEON – AEON Biopharma, Inc., $11.6M
- NMTC – Neuroone Medical Technologies Corp, $9.7M
- BCLI – Brainstorm Cell Therapeutics Inc, $9.2M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- INM – InMed Pharmaceuticals Inc, $7.6M
- ALZN – Alzamend Neuro Inc, $6.5M
- CELZ – Creative Medical Technology Holdings Inc, $6.4M
- ENVB – Enveric Biosciences Inc, $6.2M
- NRSN – Neurosense Therapeutics Ltd, $5.8M
- ADXN – Addex Therapeutics Ltd, $5.4M
- XTLB – XTL Biopharmaceuticals Ltd ADR, $4.6M
- NXL – Nexalin Technology Inc., $3.8M
- NIKI – Niki BioSolutions, Inc., $3.7M
- JUNS – Jupiter Neurosciences, Inc. Common Stock, $3.4M
- OGEN – Oragenics Inc, $1.9M
- PXMD – PaxMedica Inc. Common Stock, $88,385
- VAXX – Vaxxinity Inc, $12,678